Stay updated with breaking news from Clinical Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
30.03.2023 - - Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023 – - Completed majority of non-clinical and clinical prelaunch measures for brilaroxazine New Drug ...
Debt investment, FVOCI - equity investment or FVTPL. Financial assets are not reclassified subsequent to their initial recognition unless the Company changes its business model for... | March 29, 2023
BDC-1001 elicited objective clinical responses, including multiple PRs and long-term stable disease, across a diverse set of solid tumor types in monotherapy and in combination with... | March 29, 2023
BDC-1001 elicited objective clinical responses, including multiple PRs and long-term stable disease, across a diverse set of solid tumor types in monotherapy and in combination with nivolumabData support selection of a recommended Phase 2 dose and advance...
Phase 2 topline data readout for prevention of post-surgical abdominal adhesions on track for Q2 2023 Strong balance sheet with sufficient cash expected to fund operations into mid-2024 ... | March 23, 2023